Iktos Achieves Impressive Milestone with EIC Accelerator Grant
In an exciting development, Iktos, a frontrunner in AI-driven drug discovery, has secured a €2.5 million grant intended to bolster its cutting-edge technology. This funding, awarded by the prestigious European Innovation Council (EIC) Accelerator, marks a significant step in Iktos' mission to revolutionize how drugs are designed and developed.
Funding to Enhance AI and Robotics for Drug Discovery
This grant, potentially supplemented by an additional €5 million from the EIC, will significantly enhance Iktos' capabilities in automated synthesis and biological testing. The company's unique approach integrates AI-driven molecular generation with robotic techniques, streamlining the entire drug discovery process.
Expansion Plans and Technological Advancements
Over the coming two years, Iktos plans to enhance its drug discovery platform. This follows their strategic acquisition of Synsight and its proprietary technology, MTBench, which focuses on high-precision biological screening. These advancements are crucial for targeting complex biological factors efficiently.
The Integrated DMTA Cycle
At the core of Iktos' methodology is the DMTA (design-make-test-analyze) cycle which is orchestrated by AI. Each stage of this cycle leverages real experimental data to continuously refine the predictions made by the AI. This dynamic integration significantly reduces the time it takes to identify effective drug candidates, making the process faster and more reliable.
CEO's Statement on EIC Support
Yann Gaston-Mathé, CEO of Iktos, expressed his gratitude for the EIC's support, stating that it empowers the company to expedite the discovery of groundbreaking treatment options. Iktos is dedicated to bringing innovative therapies to patients as swiftly as possible, reflecting the European commitment to ethical and strategic innovations in AI.
Human-Centric AI Innovations
Iktos is synchronizing its platform with the EIC Accelerator Challenge, aimed at promoting human-centric generative AI developed within Europe. Their platform enhances human expertise, allowing researchers to hone in on strategic decisions, while AI streamlines molecular design and robotic synthesis.
Ensuring Ethical and Strategic Autonomy in Drug Discovery
In addition to enhancing efficiency, Iktos prioritizes ensuring that AI-generated molecules are not only theoretically promising but also practically viable for synthesis. This is achieved through a combination of virtual synthesis techniques and high-quality datasets, all validated by expert oversight, ensuring the reliability of the outputs produced.
About Iktos
Iktos has positioned itself as a global leader in the intersection of artificial intelligence and robotics for drug discovery. Its generative AI technology is designed to create molecules efficiently, tailored to meet all essential criteria for successful drug discovery. Iktos operates as a Software as a Service (SaaS) and engages in partnerships with numerous pharmaceutical entities.
The company has accomplished over 60 successful projects and is pursuing an impressive pipeline of drug candidates across various therapeutic areas such as oncology and autoimmune diseases. Iktos successfully completed a €15.5M Series A financing round, further solidifying its position in the pharmaceutical industry.
Frequently Asked Questions
What is the primary aim of the EIC Accelerator grant awarded to Iktos?
The grant aims to enhance Iktos' capabilities in AI-driven molecular generation and robotic synthesis for drug discovery.
How does Iktos' platform improve drug discovery processes?
By integrating AI at every stage of the design-make-test-analyze cycle, Iktos ensures faster and more accurate prediction of drug candidates.
What recent acquisition has supported Iktos' goals?
Iktos acquired Synsight and its MTBench technology, which aids in high-precision biological screening.
Who is the CEO of Iktos, and what did he say about the grant?
Yann Gaston-Mathé is the CEO, and he emphasized that the funding will critically accelerate the discovery of new therapeutic options for patients.
What therapeutic areas are Iktos targeting with its drug candidates?
Iktos is focusing on oncology, obesity and metabolism, as well as inflammatory and autoimmune diseases.
